Skip to main content

Figure 3.

Figure 3.

Targetable signaling pathways in non-Hodgkin lymphoma. Targetable nodes with clinically available small molecule inhibitors are ringed in red. BCR, B-cell receptor; SYK, spleen tyrosine kinase; BTK, Bruton's tyrosine kinase; PI3Kδ, phosphoinositide 3-kinases delta; NICD, Notch intracellular domain; JAK, Janus kinase; IKK, IκB kinase; HDAC, histone deacetylase.